Compounds that inhibit MCL-1 protein

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 12091425
APP PUB NO 20230052348A1
SERIAL NO

17501075

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AMGEN INCONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bedke, David Karl North Attleboro, US 2 2
Gribble,, Jr Michael W Somerville, US 8 50
Johnson, Michael G San Francisco, US 48 1204
Kohn, Todd J Thousand Oaks, US 16 71
Li, Kexue Newbury Park, US 31 127

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 17, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 17, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 17, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00